Blink Health: The Prescription Discount Platform the FTC Found Misrepresenting Which Pharmacies Would Honor Its Advertised Prices

Blink Health LLC, a prescription drug discount platform that markets heavily discounted drug prices to consumers and represents that pharmacies across the country will honor those prices, faced Federal Trade Commission charges alleging the company made materially misleading representations about the pharmacies at which its advertised prices were valid — with consumers discovering at the pharmacy counter that the discount price they had purchased through the Blink Health platform was not accepted at their preferred or local pharmacy, requiring them to either pay a higher price or travel to a more distant pharmacy that did participate in the Blink Health network.DOCUMENTED

The FTC's case against Blink Health addressed a consumer protection concern specific to the prescription drug discount marketplace: the significant consequences for patients who are unable to obtain a discount price they had counted on, given that the relevant context is a person seeking to fill a medication prescription and the harm from any friction in that process can include medication non-adherence with direct health consequences.

The Prescription Drug Discount Market

The prescription drug discount card and coupon market has grown substantially as consumers have sought ways to reduce out-of-pocket drug costs, particularly for patients without insurance coverage, those in high-deductible health plans who pay full cost before meeting their deductible, or patients whose insurance formulary does not cover a specific medication. Platforms like Blink Health, GoodRx, and similar services negotiate discount prices with pharmacy benefit managers and pharmacies, then provide consumers with discount codes or purchase prices that can be used at participating pharmacies in lieu of insurance. These platforms generate revenue through data licensing, advertising, or a portion of the transaction margin.REVIEWED

For the prescription drug discount model to provide the consumer value it promises, the participating pharmacy network must be accurate — consumers must be able to rely on the platform's representation that a specific pharmacy will honor the discount price when they arrive with their prescription. When the pharmacy network information is inaccurate — whether because the pharmacy never joined the network, left the network, or participates only for specific medications — consumers who travel to that pharmacy expecting to pay the advertised discount price discover the problem at the worst possible moment: at the pharmacy counter, prescription in hand, expecting to pick up their medication.DOCUMENTED

Why Pharmacy Counter Surprises Are Particularly Harmful

The harm from discovering at the pharmacy counter that an expected drug discount is not available is qualitatively different from the harm of discovering that an advertised price for a consumer product is not available. A consumer who discovers that an advertised price for a television is wrong can choose not to make the purchase and seek an alternative. A patient who discovers at the pharmacy counter that their expected discount price for a medication they need is not available faces a more constrained set of choices: pay the full price for a medication they may need immediately, return home without the medication and seek the discount elsewhere, or delay taking a medication with health consequences from the delay. The context of medication access makes pricing transparency in the prescription drug discount market more than a commercial fairness issue — it is a patient safety matter with direct implications for medication adherence and health outcomes.REVIEWED

This context was central to the FTC's characterization of the harm in the Blink Health case. The agency's complaint noted that consumers who experienced pharmacy counter surprises regarding Blink Health's discount prices faced situations where the harm from the pricing deception was compounded by the medical necessity of the underlying transaction. Consumers who had chosen Blink Health's platform specifically to make their medications affordable faced the worst possible disclosure point — discovering the platform's limitation when they were attempting to fill a prescription they needed for their health — rather than at a point in the purchase process where they could have made an informed alternative choice.DOCUMENTED

Finding out at the pharmacy counter that your discount card does not work here is not the same as finding out a sale price is wrong at a grocery store. The patient needs the medication. The disclosure failure happens at the worst possible moment — and for patients with chronic conditions on maintenance medications, it can happen repeatedly.

Network Accuracy and Platform Obligations

The FTC's case against Blink Health established that prescription drug discount platforms have an obligation to maintain accurate pharmacy network information — and that representing pharmacies as participating when they are not, or when participation is qualified in ways not disclosed to consumers, constitutes deceptive advertising under the FTC Act. The platform's value proposition — providing consumers with access to discount prices at pharmacies they can readily reach — depends fundamentally on the accuracy of the pharmacy participation information the platform provides. When that information is materially inaccurate, the platform is not delivering the service it advertises and is causing consumer harm in a context where the consequences of the deception are particularly significant.DOCUMENTED

The settlement required Blink Health to implement systems to maintain accurate pharmacy participation information, to verify participation status before representing pharmacies as accepting the platform's discount prices, and to disclose any limitations on pharmacy participation — including geographic restrictions, formulary limitations, or other factors that might affect whether a specific consumer can obtain the advertised price at a specific location — in a manner that is clear and prominent enough to inform consumers before they travel to a pharmacy expecting a price they may not be able to obtain. These requirements address the root cause of the consumer harm: inaccurate information provided at a critical decision point in the prescription drug purchasing process.

Implications for Prescription Drug Pricing Transparency

The Blink Health case has broader implications for the prescription drug pricing transparency landscape, where multiple platforms — GoodRx, RxSaver, NeedyMeds, and others — compete to provide consumers with drug discount information. For consumers choosing among these platforms, pharmacy network accuracy — the reliability of the platform's representation that specific pharmacies will honor the advertised prices — is a material factor in selecting which platform to use for any specific prescription. The FTC's enforcement action against Blink Health signals that the agency views pharmacy network accuracy as a consumer protection obligation for these platforms and that misrepresentations about pharmacy participation will be subject to enforcement. Consumers can protect themselves by verifying directly with their pharmacy before traveling that the discount code or price they have obtained from a third-party platform will be accepted — a verification step that adds friction but can prevent the pharmacy counter surprise that Blink Health's customers experienced.

Have documents relevant to this story? Reach us through our tips channel.